Zhaoniya: Shanghai-based Mobile Pharmaceutical Platform

September 5, 2013 Leave a comment

Zhaoniya: Shanghai-based Mobile Pharmaceutical Platform

By Emma Lee on September 4, 2013

QQ截图20130904104045

Zhaoniya, also known as Uyi Uyao, is a mobile app targeted to balance the demands of pharmacies and patients. The app provides separate apps for merchants and users. Zhaoniya distributes orders placed by users to pharmacies within 2 miles of the user’s location. The pharmacists will connect the patients after receiving the orders to give professional advices and to decide which kind of medicine to deliver. The app now provides free service to both pharmacies and patients. But the customers are allowed to pay extra tips to pharmacies, especially when the medicine has to be delivered at night.Zhaoniya offers both Web and App access for pharmacies, which can define their delivery distances by themselves. The monthly turnover of brick-and-mortar drug stores advanced around 10% after using this app, according to Chen Xiaofeng, founder of the company.

Zhaoniya has established cooperation relationship with more than 600 drug stores in Shanghai, covering both individual and chain stores like For me, Deyi and Kaixinren. Chen aims to cover more than 2,000 Shanghai drug stores in next six months, achieving a coverage rate of 40%. The firm also planned to make foray into Beijing market.

In the long term, Zhaoniya planned to introduce doctors into the platform, creating an ecosystem for the three parties of doctors, pharmacies and patients, according to Chen.

The company’s founder Chen Xiaofeng is an experienced entrepreneur. He was the co-founders of digital magazine VIKA (acquired by Sina) and mobile reading app Zaker.

The market size of pharmaceutical industry reached 250 billion yuan in 2012, increasing at an annual growth rate of 18% to 20% (report in Chinese).

– See more at: http://technode.com/2013/09/04/zhaoniya-shanghai-based-mobile-pharmaceutical-platform/#sthash.hOamxDs6.dpuf

Filed under TMT Trends

Unknown's avatarAbout bambooinnovator
Kee Koon Boon (“KB”) is the co-founder and director of HERO Investment Management which provides specialized fund management and investment advisory services to the ARCHEA Asia HERO Innovators Fund (www.heroinnovator.com), the only Asian SMID-cap tech-focused fund in the industry. KB is an internationally featured investor rooted in the principles of value investing for over a decade as a fund manager and analyst in the Asian capital markets who started his career at a boutique hedge fund in Singapore where he was with the firm since 2002 and was also part of the core investment committee in significantly outperforming the index in the 10-year-plus-old flagship Asian fund. He was also the portfolio manager for Asia-Pacific equities at Korea’s largest mutual fund company. Prior to setting up the H.E.R.O. Innovators Fund, KB was the Chief Investment Officer & CEO of a Singapore Registered Fund Management Company (RFMC) where he is responsible for listed Asian equity investments. KB had taught accounting at the Singapore Management University (SMU) as a faculty member and also pioneered the 15-week course on Accounting Fraud in Asia as an official module at SMU. KB remains grateful and honored to be invited by Singapore’s financial regulator Monetary Authority of Singapore (MAS) to present to their top management team about implementing a world’s first fact-based forward-looking fraud detection framework to bring about benefits for the capital markets in Singapore and for the public and investment community. KB also served the community in sharing his insights in writing articles about value investing and corporate governance in the media that include Business Times, Straits Times, Jakarta Post, Manual of Ideas, Investopedia, TedXWallStreet. He had also presented in top investment, banking and finance conferences in America, Italy, Sydney, Cape Town, HK, China. He has trained CEOs, entrepreneurs, CFOs, management executives in business strategy & business model innovation in Singapore, HK and China.

Leave a comment